Get started
Author

Toshiki Yamada

Observed names: T Yamada, T. Yamada, Yamada, Toshiki
Observed institutions: Akita University, Gifu Municipal Hospital, Gifu University Hospital, Gifu Prefectural General Medical Center, Gifu University, Institute of Medical Science, The University of Tokyo, The University of Tokyo, Nippon Medical School
ORCID: 0000-0001-7550-8130
Observed ORCID: 0000-0001-7550-8130
OpenAlex ID: A5103001950
Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies
2004 · Satoshi Takahashi, Tohru Iseki, et al. · Blood · 325
Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia
2003 · Jun Ooi, Tohru Iseki, et al. · Blood · 105
Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy
2005 · Shinji Takai, Hisashi Tsurumi, et al. · European Journal Of Haematology · 95
Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin?s lymphoma: in combination with the International Prognostic Index
2004 · Hideko Goto, Hisashi Tsurumi, et al. · Journal of Cancer Research and Clinical Oncology · 66
A phase II study of a THP‐COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B‐cell lymphoma
2007 · Hisashi Tsurumi, Takeshi Hara, et al. · Hematological Oncology · 48
Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma
2000 · Takeshi Hara, Hisashi Tsurumi, et al. · American Journal of Hematology · 43
Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin?s lymphoma
2004 · Hisashi Tsurumi, Toshiki Yamada, et al. · Journal of Cancer Research and Clinical Oncology · 42
R‐THP‐COP versus R‐CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open‐label, noninferiority phase 3 trial
2018 · Takeshi Hara, Takeshi Yoshikawa, et al. · Hematological Oncology · 40
Serum‐soluble tumor necrosis factor receptor 2 (sTNF‐R2) level determines clinical outcome in patients with aggressive non‐Hodgkin's lymphoma
2006 · Naoe Goto, Hisashi Tsurumi, et al. · European Journal Of Haematology · 39
Necrosis of hepatocellular carcinoma as a result of subintimal injury incurred by hepatic angiography: report of two cases.
1986 · K Takayasu, Y Muramatsu, et al. · PubMed · 36
Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)
2008 · Jun-ichi Kitagawa, Takeshi Hara, et al. · Journal of Cancer Research and Clinical Oncology · 35
Fas and Fas ligand expression on germinal center type‐diffuse large B‐cell lymphoma is associated with the clinical outcome
2006 · Yasushi Kojima, Hisashi Tsurumi, et al. · European Journal Of Haematology · 35
PDF
Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone
2012 · Naoe Goto, Hisashi Tsurumi, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 31
Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies
2010 · Naoe Goto, Takeshi Hara, et al. · American Journal of Hematology · 31
A prospective study of P‐IMVP‐16/CBDCA: a novel salvage chemotherapy for patients with aggressive non‐Hodgkin's lymphoma who had previously received CHOP therapy as first‐line chemotherapy
2002 · Michio Sawada, Hisashi Tsurumi, et al. · European Journal Of Haematology · 30
Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens: Serum IL-18 for DLBCL
2011 · Naoe Goto, Hisashi Tsurumi, et al. · European Journal Of Haematology · 29
Phase II study of the tetrahydropyranyl adriamycin–cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma
2011 · Senji Kasahara, Takeshi Hara, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 28
Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation
2004 · Akira Tomonari, Tohru Iseki, et al. · Annals of Hematology · 24
Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor
2002 · Senji Kasahara, Takeshi Hara, et al. · British Journal of Haematology · 23
TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy
2023 · Toshiki Yamada, Megumi Tatematsu, et al. · The Journal of Experimental Medicine · 22
PDF
Trained innate lymphoid cells in allergic diseases
2020 · Takashi Ebihara, Megumi Tatematsu, et al. · Allergology International · 22
PDF
Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma
2009 · Takeshi Hara, Hisashi Tsurumi, et al. · Journal of Cancer Research and Clinical Oncology · 22
Late Reactivation of Hepatitis B Virus after Chemotherapies for Hematological Malignancies: A Case Report and Review of the Literature
2016 · Toshiki Yamada, Yasuhito Nannya, et al. · Internal Medicine · 19
PDF
Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B‐cell lymphoma treated with the R‐ CHOP regimen
2013 · Nobuhiko Nakamura, Naoe Goto, et al. · European Journal Of Haematology · 19
Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis
2011 · Soranobu Ninomiya, Nobuhiro Kanemura, et al. · International Journal of Hematology · 19
Works count: 96
Citation count: 1,539
H-index: 22
I10-index: 37
Year
Topic
Type